Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205634 · ClinicalTrials.gov registry record · Phase 2
Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis
A Phase 2 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00205634 is a Phase 2 study that has completed, run by Wake Forest University. The registered enrollment target is 50 participants.
The verdict
NCT00205634, a Phase 2 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether Biaxin (clarithromycin) improves sputum abnormalities, lung function, and overall feeling of well-being in people with cystic fibrosis (CF). Biaxin is an antibiotic commonly used for the treatment of respiratory infections in people who do not have CF, and is sometimes used in CF patients as well. Studies done in a disease called diffuse panbronchiolitis (which is similar to CF) and some preliminary studies that have been done in CF patients suggest that Biaxin might have a beneficial effect on CF sputum in ways unrelated to its antibiotic activity.
Interventions
- DRUG Biaxin ( clarithromycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2000-12 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205634
The ClinicalTrials.gov registry entry for NCT00205634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biaxin ( clarithromycin) is the first listed.
NCT00205634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205634 about?
NCT00205634 is a clinical study titled "Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis". The purpose of this study is to evaluate whether Biaxin (clarithromycin) improves sputum abnormalities, lung function, and overall feeling of well-being in people with cystic fibrosis (CF). Biaxin is an antibiotic commonly used for the treatment of respiratory infections in people who do not have CF...
What is the current status of trial NCT00205634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2000-12. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00205634?
The interventions under investigation include: Biaxin ( clarithromycin) (DRUG).
Who is sponsoring clinical trial NCT00205634?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.